Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.09 and traded as low as $4.62. Bolt Biotherapeutics shares last traded at $4.6830, with a volume of 4,843 shares traded.

Analysts Set New Price Targets

BOLT has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price target for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $34.67.

Bolt Biotherapeutics Trading Down 0.8%

The business’s fifty day moving average price is $4.79 and its 200 day moving average price is $5.09. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $8.99 million, a PE ratio of -0.29 and a beta of 1.12.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.50 million. Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%. As a group, analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P acquired a new stake in Bolt Biotherapeutics in the 4th quarter worth about $112,000. Shay Capital LLC purchased a new stake in Bolt Biotherapeutics in the 3rd quarter valued at about $85,000. Renaissance Technologies LLC increased its stake in shares of Bolt Biotherapeutics by 92.2% during the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth about $89,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after acquiring an additional 2,448 shares during the period. 86.70% of the stock is currently owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.